Palvella Therapeutics, Inc. (PVLA)
NASDAQ: PVLA · Real-Time Price · USD
24.36
-1.03 (-4.06%)
Apr 28, 2025, 4:00 PM EDT - Market closed

Palvella Therapeutics Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022
Period Ending
Dec '24 Dec '23 Dec '22
Cash & Equivalents
83.67.3516.05
Cash & Short-Term Investments
83.67.3516.05
Cash Growth
1037.44%-54.21%-
Accounts Receivable
0.36--
Other Receivables
1.98--
Receivables
2.34--
Prepaid Expenses
2.30.20.47
Total Current Assets
88.237.5516.52
Total Assets
88.237.5516.52
Accounts Payable
4.590.943.18
Accrued Expenses
4.291.262.44
Other Current Liabilities
3.170.170.16
Total Current Liabilities
12.042.365.78
Long-Term Debt
11.948.0532.42
Other Long-Term Liabilities
1.651.011.5
Total Liabilities
25.6311.4339.7
Common Stock
0.01--
Additional Paid-In Capital
156.331.821.22
Retained Earnings
-93.74-76.3-94.99
Comprehensive Income & Other
0--
Total Common Equity
62.61-74.48-93.78
Shareholders' Equity
62.61-3.88-23.17
Total Liabilities & Equity
88.237.5516.52
Total Debt
11.948.0532.42
Net Cash (Debt)
71.66-0.7-16.36
Net Cash Per Share
32.19-0.39-2.86
Filing Date Shares Outstanding
11.025.725.72
Total Common Shares Outstanding
11.015.725.72
Working Capital
76.25.1910.74
Book Value Per Share
5.69-13.02-16.40
Tangible Book Value
62.61-74.48-93.78
Tangible Book Value Per Share
5.69-13.02-16.40
Updated Dec 16, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q